Skip to content

US · MENS · BIOTECHNOLOGY

Jyong Biotech Ltd. Ordinary Shares (MENS) intrinsic value and stock valuation

$1.45as of 2026-11-21 · Mkt cap 155.86M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Jyong Biotech Ltd. Ordinary Shares DCF and intrinsic value

InvestorsCraft values MENS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MENS’s statements →

Jyong Biotech Ltd. Ordinary Shares Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Taipei City, TP 221 jyongbio.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-4.67M
20202025
Free cash flow
-$-3.04M
20202025
Total equity
-$-24.91M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-2.61M-$-2.06M-$-2.8M-$-2.83M-$-2.4M
Net income-$-4.67M-$-3.02M-$-4.4M-$-6.63M-$-4.2M
EPSd-$-63.96K-$-39.72K-$-57.87K-$-87.2K-$-55.24K
Operating cash flow-$-3.04M-$-3.62M-$-2.6M-$-2.97M-$-1.98M
Capital expenditure$0.00$0.00$0.00-$-250K-$-140K
Free cash flow-$-3.04M-$-3.62M-$-2.6M-$-3.22M-$-2.12M
Total assets$20.8M$6.37M$8.25M$8.74M$9.43M
Total debt$18.6M$18.1M$16.7M$14.3M$11.8M
Net debt$17.4M$18M$16.5M$13.5M$11.2M
Total equity-$-24.91M-$-36.52M-$-34.07M-$-29.63M-$-23.32M
Cash and short-term investments$1.18M$100K$180K$810K$2.38M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$100K$120K$130K$120K$120K
Gross profit-$-100K-$-120K-$-130K-$-120K-$-120K
Research and development expenses$730K$930K$1.07M$1.29M$1.56M
Selling, general and administrative expenses$1.78M$1.13M$1.73M$1.54M$840K
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$2.51M$2.06M$2.8M$2.83M$2.4M
Cost and expenses$2.61M$2.06M$2.8M$2.83M$2.4M
Interest income$610K$10K$60K$10K$10K
Interest expense$2.54M$1.03M$760K$770K$830K
Depreciation and amortization$100K$120K$130K$120K$120K
Ebitda-$-2.51M-$-1.86M-$-3.52M-$-5.74M-$-3.24M
Operating income-$-2.61M-$-2.06M-$-2.8M-$-2.83M-$-2.4M
Total other income/expenses, net-$-2.06M-$-960K-$-1.6M-$-3.8M-$-1.79M
Income before tax-$-4.67M-$-3.02M-$-4.4M-$-6.63M-$-4.2M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-4.67M-$-3.02M-$-4.4M-$-6.63M-$-4.2M
Weighted average shares outstanding$73M$76M$76M$76M$76M
Weighted average diluted shares outstanding$73M$76M$76M$76M$76M
Balance sheet
20252024202320222021
Cash and short-term investments$1.18M$100K$180K$810K$2.38M
Net receivables$13.5M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$15.5M$210K$1.84M$2.46M$2.65M
Property, plant and equipment, net$5.23M$3.19M$3.54M$6M$6.78M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.24M$6.16M$6.41M$6.28M$6.78M
Total assets$20.8M$6.37M$8.25M$8.74M$9.43M
Accounts payable$0.00$0.00$0.00$0.00$50K
Short-term debt$8.36M$7.44M$8.1M$7.82M$5.18M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$34.8M$12.1M$14.3M$12.9M$6.29M
Long-term debt$10.2M$10.7M$8.59M$6.43M$6.61M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$10.9M$30.8M$28.1M$25.5M$26.5M
Capital lease obligations$30K$170K$200K$280K$600K
Total liabilities$45.7M$42.9M$42.3M$38.4M$32.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-37.75M-$-33.08M-$-30.06M-$-25.66M-$-19.03M
Accumulated other comprehensive income (loss)$680K$1.12M$550K$590K$270K
Total equity-$-24.91M-$-36.52M-$-34.07M-$-29.63M-$-23.32M
Total investments$0.00$0.00$0.00$90K$1.83M
Total debt$18.6M$18.1M$16.7M$14.3M$11.8M
Net debt$17.4M$18M$16.5M$13.5M$11.2M
Cash flow statement
20252024202320222021
Net income-$-4.67M-$-3.02M-$-4.4M-$-6.63M-$-4.2M
Depreciation and amortization$100K$120K$130K$120K$120K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$20.7M-$-1.49M$1.12M$2.94M$1.24M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$0.00$0.00-$0.00-$-30K$20K
Net cash provided by operating activities-$-3.04M-$-3.62M-$-2.6M-$-2.97M-$-1.98M
Investments in property, plant and equipment$0.00$0.00$0.00-$-250K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-13.51M$0.00$100K$1.39M-$-1.31M
Common stock issued$17.8M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.6M$1.99M$2.03M$3.33M-$-1.38M
Net change in cash$1.08M-$-1.64M-$-530K$1.72M-$-4.61M
Cash at end of period$1.18M$100K$1.74M$2.27M$550K
Operating cash flow-$-3.04M-$-3.62M-$-2.6M-$-2.97M-$-1.98M
Capital expenditure$0.00$0.00$0.00-$-250K-$-140K
Free cash flow-$-3.04M-$-3.62M-$-2.6M-$-3.22M-$-2.12M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Jyong Biotech Ltd. Ordinary Shares

        Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

        CEO
        Fu-Feng Kuo
        Employees
        27
        Beta
        2.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Jyong Biotech Ltd. Ordinary Shares (MENS)?

        InvestorsCraft does not currently publish an intrinsic value for MENS. How the IC value is calculated.

        Is MENS undervalued?

        InvestorsCraft does not publish an undervaluation signal for MENS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.